Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iQ-007 in healthy volunteers
NCT06899230Phase 1Active, not recruiting
- Sponsor
- iQure Pharma Inc.
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iQ-007 in focal seizure and epilepsy (4 arms), sponsored by iQure Pharma Inc. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 9 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
iQ-007
03
Conditions
focal seizureepilepsy
Beyond the preview
Go deeper on NCT06899230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899230.